Virtual ISPOR

Study Evaluates Insulin Availability in the Philippines

May 30th 2021

There is low insulin availability in the Philippines and investigators recommend policy and regulatory reviews.

Infliximab Study Yields Evidence of Biosimilar Equivalence

May 24th 2021

Adjusting for variables, investigators found little difference in disease outcomes for patients who switched to the infliximab originator vs biosimilars.

AbbVie Study Highlights Switching Costs for Rheumatic Biosimilars

May 20th 2021

Article

A study funded by AbbVie finds support for maintaining patients on originator rheumatic agents, such as Humira (adalimumab), rather than switching to biosimilars.

Kaiser Permanente Investigators Confirm Mvasi Safety and Efficacy in Population With Nonsquamous NSCLC

May 18th 2021

Article

The retrospective, real-world study (N = 353) conducted within the Kaiser Permanente network followed the July 2019 launch of the bevacizumab biosimilar Mvasi.

German Study Calculates Adalimumab Biosimilar Savings From Earlier Intervention

May 17th 2021

Article

Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).

Canada Grapples With Drug Price Escalation

May 21st 2020

Article

In July 2020 Canada will implement a series of reforms to help bring runaway drug prices under control, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

Study Shows Variations in RWE Citation Frequency

May 20th 2020

Article

Real world evidence (RWE) was cited differently depending on a number of criteria, leaving the door open to future research on how RWE influences payer decision making for specialty drug plans, said presenting author, Ari Panzer, at the Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

ISPOR Panelists Weigh the Success of APMs

May 19th 2020

Article

The alternative payment model (APM) doesn’t perfectly balance the competing interests of revenue growth and value-based care, but it has been a learning tool, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

Panelists Advocate for Global Collaboration in RWE Effort

May 19th 2020

Article

Harmonized efforts across global borders and among stakeholders are needed to generate and build acceptance of real world evidence (RWE) to actively aid in health care decision making, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

International Reference Pricing Gets Thumbs-Down From ISPOR Panel

May 18th 2020

Article

There’s not enough study of the effects of international reference pricing, but it is likely to stifle innovation and create access problems, according to an expert panel at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.